Get a free sample of Tuberculosis Diagnostics Test Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Tuberculosis Diagnostics Test Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Tuberculosis Diagnostics Test Market Size
Tuberculosis Diagnostics Test Market size was valued at USD 2.3 billion in 2023 and is anticipated to register a CAGR of over 5.5% between 2024 and 2032. Tuberculosis diagnostics tests are medical procedures and analyses employed in the detection and diagnosis of tuberculosis (TB, a bacterial infection caused by Mycobacterium tuberculosis. These tests are crucial for identifying individuals with active TB disease or latent TB infection, enabling prompt treatment and prevention efforts. The rising prevalence of TB significantly fuels the market.
For instance, according to World Health Organization (WHO), in 2022, TB caused 1.3 million deaths, including 167,000 co-infected with HIV, making it the second leading infectious cause of death worldwide, surpassing HIV/AIDS. There were around 10.6 million new TB cases, affecting 5.8 million men, 3.5 million women, and 1.3 million children, highlighting its global prevalence across all demographics. Thus, as the incidence of TB increases globally, there is a higher demand for early detection and effective treatment, prompting healthcare providers and diagnostic companies to innovate and adopt advanced technologies, stimulating market growth.
Furthermore, the adoption of Point-of-Care Testing (POCT) which is estimated to reach USD 78 billion revenue by 2032, which involves conducting diagnostic tests at or near the patient's location, is a key driver due to its rapid results and ability to facilitate immediate treatment initiation. Particularly crucial for tuberculosis, where early detection is paramount, POCT proves invaluable in regions with limited access to centralized laboratories.
Why is the U.S. tuberculosis diagnostics test industry growing?
U.S. tuberculosis diagnostics test market accounted for USD 846 million in 2023 and is predicted to witness substantial growth through 2032, favored by the advanced healthcare infrastructure, a robust R&D landscape, and a high prevalence of TB in the region.
How will pathological laboratories influence tuberculosis diagnostic tests industry growth?
The pathological laboratories segment garnered USD 1.20 billion revenue in 2023, attributed to the crucial role in conducting sophisticated diagnostic tests, including Nucleic Acid Amplification Tests (NAATs), molecular assays, and other pathological screening.
How big is tuberculosis diagnostics test market?
The global tuberculosis diagnostics test industry was valued at USD 2.3 billion in 2023 and is estimated to reach USD 3.7 billion by 2032, owing to the rising prevalence of TB.
Who are the key players in tuberculosis diagnostics test industry?
Abbott Laboratories, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Siemens Healthineers AG., bioM